Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series
Haemophilia · 2024
DOI: 10.1111/hae.15094 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Haemophilia, 2024. Verfasst von Kimberley Youkhana und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Capel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Introduction
The management of bleeding events (BEs) in haemophilia A (HA) and B (HB) patients with inhibitors necessitates the use of bypassing agents. The recombinant factor VIIa bypassing agent eptacog beta has demonstrated efficacy at treating BEs and managing perioperative bleeding in adults in phase three clinical studies.
Aim
To provide real‐world descriptions of eptacog beta use for BE treatment in patients on emicizumab or eptacog beta prophylaxis.
Methods
This is a retrospective case series of 14 patients who received eptacog beta at seven haemophilia treatment centres, with HA ( n = 11) or HB ( n = 3) and inhibitors or anaphylaxis to factor replacement.
Results
Twenty‐four spontaneous and traumatic BEs are described (muscle hematomas, joint hemarthroses, port site, and epistaxis) involving 11 subjects. Eptacog beta was effective for acute bleed treatment as both first‐line therapy and for treatment of BEs refractory to eptacog alfa in 23/24 events. When eptacog beta was used for prophylaxis, 2/3 patients reported a decreased frequency of breakthrough BEs compared with prophylactic eptacog alfa and one patient experienced a similar frequency of breakthrough BEs compared with prophylactic activated prothrombin complex concentrate. Eptacog beta provided effective bleed control for three subjects who underwent minor surgical procedures. Treatment with eptacog beta was estimated to be 46%–72% more cost‐effective than eptacog alfa. No safety concerns or adverse events were reported.
Conclusions
In this case series, eptacog beta was safe, effective, and economical as first‐line therapy, treatment of refractory BEs, management of perioperative bleeding, or prophylaxis in haemophilia patients with inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina School of Medicine, Capel Hill, North Carolina, USA.
- Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Cohen Children's Medical Center, Northwell Health, New Hyde Park, New York, USA.
- Oklahoma Center for Bleeding and Clotting Disorders at OU Health, Oklahoma City, Oklahoma, USA.
- Department of Hematology and Medical Oncology, and the Hemophilia of Georgia Center for Bleeding & Clotting Disorders, Emory University, Atlanta, Georgia, USA.
- State University of New York Upstate Medical Center, Syracuse, New York, USA.
ORCID-Profile: Kimberley Youkhana, Glaivy Batsuli, Duc Q Tran, Guy Young, Robert Sidonio, Yasmina Abajas
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Youkhana, K., Batsuli, G., Acharya, S., Khan, O., Tran, D. Q., Dvorak, A., Recht, M., Young, G., Sidonio, R., & Abajas, Y. (2024). Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia. https://doi.org/10.1111/hae.15094
Vancouver
Youkhana K, Batsuli G, Acharya S, Khan O, Tran DQ, Dvorak A, et al. Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia. 2024. doi:10.1111/hae.15094
BibTeX
@article{Youkhana2024,
author = {Youkhana, Kimberley and Batsuli, Glaivy and Acharya, Suchitra and Khan, Osman and Tran, Duc Q and Dvorak, Andrea and Recht, Michael and Young, Guy and Sidonio, Robert and Abajas, Yasmina},
title = {Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15094}
}
EUVIMED